Search results for "severe disease"

showing 5 items of 15 documents

Comparing medical treatments for Crohn’s disease

2013

The drugs available for inflammatory bowel disease are aminosalicylates, antibiotics, steroids, immunosuppressors and biologics. The effectiveness of these drugs has been evaluated in many randomized clinical trials, mainly versus placebo. Few studies have been conducted comparing the different drugs among themselves, owing to the methodological problems raised by comparative trials, such as sample size and blindness. This review focuses mainly on the randomized clinical trials that have compared different treatments. Of course comparisons are mainly between drugs used in a particular setting (mild, moderate and severe disease). However, on many occasions there is no homogeneity in these cl…

medicine.medical_specialtyPathologymedicine.drug_classAntibioticsAlternative medicineSevere diseasePlaceboInflammatory bowel diseaselaw.inventionBiological FactorsCrohn DiseaseRandomized controlled trialAdrenal Cortex HormoneslawInternal medicineAzathioprineIntestinal FistulaSecondary PreventionmedicineHumansBudesonideRandomized Controlled Trials as TopicCrohn's diseasebusiness.industryProbioticsHealth Policymedicine.diseaseAnti-Bacterial AgentsAminosalicylic AcidsMethotrexateSample size determinationbusinessJournal of Comparative Effectiveness Research
researchProduct

Antibiotic resistance among Shigella serogroups isolated in Tehran, Iran (2002-2004)

2009

Shigellosis, one of the most common bacterial diarrhoeal diseases, is endemic throughout the world. It is one of the major causes of morbidity in children with diarrhoea in Iran [1-4]. Antibiotic therapy is useful and effective for shigellosis. Treatment is critical for persons with severe disease, particularly children and immunosuppressed patients. Use of an appropriate antibiotic therapy can shorten the duration of symptoms, significantly reduce the risk of transmission, and also prevent potentially lethal complications [5-7]. However, high frequencies of resistance in

medicine.medical_specialtyShigellosisSevere diseaseIranSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeMicrobiologyMicrobiologyAntibiotic resistanceVirologyAntibiotic therapyInternal medicineDrug Resistance BacterialmedicineHumansShigellaChildDysentery BacillaryShigella Antibiotic resistance IranTransmission (medicine)Diarrhoeal diseasebusiness.industryGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesChild PreschoolParasitologyShigellabusinessThe Journal of Infection in Developing Countries
researchProduct

FRI0056 Joint damage in patients with rheumatoid arthritis over 15-20 years – are there differences between women and men?

2013

Background Rheumatoid arthritis (RA) is suggested to be a more severe disease in women than in men as disease activity appears higher in women and men meet remission criteria more often than women do. Long-term severity of RA can be analyzed from permanent joint damage in radiographs. Objectives To study possible differences in the extent of radiographic joint damage between women and men in four early RA cohorts with 15 or more years of prospective follow-up. Methods Early RA cohorts with prospective longitudinal observations include following cohorts: Jyvaskyla Central Hospital with 70 patients from 1990’s (JYV1990) and 135 patients from the 1980’s (JYV1980), Lund University Hospital with…

medicine.medical_specialtybusiness.industryImmunologySevere diseasemedicine.diseaseUniversity hospitalGeneral Biochemistry Genetics and Molecular BiologySurgeryRheumatologyRemission criteriaRheumatoid arthritisInternal medicineJoint damageEarly ramedicineImmunology and AllergyIn patientbusinessRheumatismAnnals of the Rheumatic Diseases
researchProduct

Standard Therapeutic Approach and New Therapies

2015

The traditional approach to therapy of Crohn’s disease has been the step-up approach usually represented as a pyramid (Fig. 7.1) where, progressing from mild to severe disease, therapeutic choices proceed step by step from less potent drugs at the basement of the pyramid to more potent but also more toxic drugs at the top. The advent of biological therapies and the wider use of immunomodulators, together with the opportunity to achieve ambitious treatment goals and possibly to modify the course of disease, have led to other approaches such as the accelerated step-up or the top-down approach. This means that immunomodulators and biologics can be used earlier and de-escalated when disease is …

medicine.medical_specialtybusiness.industryProgressive multifocal leukoencephalopathyfood and beveragesSevere diseaseDiseaseTreatment goalsmedicine.diseaseDisease courseTherapeutic approachPyramidMedicineCertolizumab pegolbusinessIntensive care medicinemedicine.drug
researchProduct

AB0465 Etanercept therapy in rheumatoid arthritis patients with moderate or severe disease activity

2013

Background Rheumatoid arthritis (RA) is conventionally defined as moderate when the disease activity score assessed in 28 joints (DAS28) is ≥3.2, and high disease with DAS28 >5.1 Objectives Aim of this analysis was to evaluate the rate of remission and LDA (low disease activity), in RA patients starting etanercept therapy with moderate disease activity in the real world settings Methods The clinical records were retrospectively analysed from the Italian nationwide registry, called GISEA (Gruppo Italiano Studio Early Arthritis). RA patients with moderate (Mod-RA) and high (H-RA) disease activity (DAS28 >3.2) with incomplete response to conventional DMARDs and beginning a treatment with etane…

musculoskeletal diseasesModerate to severemedicine.medical_specialtybusiness.industryImmunologySevere diseaseDiseasemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyEtanerceptSurgeryRheumatologyStandard careRheumatoid arthritisInternal medicineImmunology and AllergyMedicineEtanercept therapybusinessEarly arthritismedicine.drugAnnals of the Rheumatic Diseases
researchProduct